Merck KGaA and GSK’s Bintrafusp Alfa Fails to Meet its Co-Primary Endpoints in Lung Cancer Study

 Merck KGaA and GSK’s Bintrafusp Alfa Fails to Meet its Co-Primary Endpoints in Lung Cancer Study

Merck KGaA and GSK’s Bintrafusp Alfa Fails to Meet its Co-Primary Endpoints in Lung Cancer Study

Shots:

  • Merck KgaA provides an update on its P-III INTR@PID Lung 037 study and the extensive INTR@PID clinical trial program assessing bintrafusp alfa for patients with BTC and cervical cancer
  • Based on the IDMC’s recommendation, Merck will discontinue the INTR@PID Lung 037 study as it fails to meet its co-1EPs, specifically PFS. The ongoing clinical trial INTR@PID Lung 037 includes 1L treatment of patients with stage IV NSCLS having PD-L1 expression
  • The company will further evaluate bintrafusp alfa in other studies. GSK has high hopes with the drug as it has paid $4.2B+ in the collaboration signed in 2019

Click here ­to­ read full press release/ article | Ref: Merck KgaA | Image: GMP News

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post